<DOC>
	<DOC>NCT01021852</DOC>
	<brief_summary>This was a cross-over, polysomnography (PSG) study to test the safety, tolerability and effectiveness of different doses of MK-6096 in the treatment of participants with primary insomnia. The primary efficacy hypothesis was that at least one dose of MK-6096 is superior to placebo in improving sleep efficiency (SE) as measured by PSG on Night 1 and at the end of 4 weeks of treatment (Week 4).</brief_summary>
	<brief_title>Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<criteria>Participant is willing to stay overnight at a sleep laboratory on 6 separate nights and is willing to stay in bed for at least 8 hours each night while at the sleep laboratory Participant's regular bedtime is between 9 PM and 12 AM (midnight) Participant is able to read and complete questionnaires and diaries Participant is willing to refrain from napping during the study If female, participant is breast feeding, pregnant, or planning to become pregnant Participant is expecting to donate eggs or sperm during the study Participant has any history of a neurological disorder Participant has a history within the past 6 months of a cardiovascular disorder such as unstable angina, congestive heart failure or acute coronary syndrome. Participant has difficulty sleeping due to a medical condition Participant has donated blood products within the 8 weeks prior to the study Participant plans to travel across 3 or more time zones during the study Participant is currently participating or has participated in a study with an investigational compound or device within the last 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>